| [1] |
中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国抗癌协会肝癌专业委员会, 中国医师协会肝癌专业委员会, 等. 肝细胞癌新辅助及转化治疗中国专家共识(2023版)[J/CD]. 肝癌电子杂志, 2022, 9(1): 23-28.
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
Liu H, Jiao Z, Han W, et al. Identifying the histologic subtypes of non-small cell lung cancer with computed tomography imaging: a comparative study of capsule net, convolutional neural network, and radiomics[J]. Quant Imaging Med Surg, 2021, 11(6): 2756-2765. DOI: 10.21037/qims-20-734.
|
| [6] |
Wang L, Yang W, Xie X, et al. Application of digital mammography-based radiomics in the differentiation of benign and malignant round-like breast tumors and the prediction of molecular subtypes[J]. Gland Surg, 2020, 9(6): 2005-2016. DOI: 10.21037/gs-20-473.
|
| [7] |
Akai H, Yasaka K, Kunimatsu A, et al. Predicting prognosis of resected hepatocellular carcinoma by radiomics analysis with random survival forest[J]. Diagn Interv Imag, 2018, 99(10): 643-651. DOI: 10.1016/j.diii.2018.05.008.
|
| [8] |
Zhu Y, Mao Y, Chen J, et al. Radiomics-based model for predicting early recurrence of intrahepatic mass-forming cholangiocarcinoma after curative tumor resection[J]. Sci Rep, 2021, 11(1): 18347. DOI: 10.1038/s41598-021-97796-1.
|
| [9] |
|
| [10] |
He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720. DOI: 10.1177/17588359211002720.
|
| [11] |
Zhang W, Hu B, Han J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients[J]. Front Oncol, 2021, 11: 747950. DOI: 10.3389/fonc.2021.747950.
|
| [12] |
Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol, 2015, 63(1): 83-92. DOI: 10.1016/j.jhep.2015.01.023.
|
| [13] |
Habibollahi P, Shamchi SP, Choi JM, et al. Association of complete radiologic and pathologic response following locoregional therapy before liver transplantation with long-term outcomes of hepatocellular carcinoma: a retrospective study[J]. J Vasc Interv Radiol, 2019, 30(3): 323-329. DOI: 10.1016/j.jvir.2018.11.037.
|
| [14] |
Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011[J]. Liver Int, 2012, 32(7): 1053-1063. DOI: 10.1111/j.1478-3231.2012.02792.x.
|
| [15] |
Han JH, Kim DG, Na GH, et al. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(45): 17132-17140. DOI: 10.3748/wjg.v20.i45.17132.
|
| [16] |
Choi J, Kim GA, Han S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma[J]. Hepatology, 2019, 69(5): 1983-1994. DOI: 10.1002/hep.30233.
|
| [17] |
Hughes DM, Berhane S, Emily de Groot CA, et al. Serum levels of α-fetoprotein increased more than 10 years before detection of hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2021, 19(1): 162-170. e4. DOI: 10.1016/j.cgh.2020.04.084.
|
| [18] |
Citores MJ, Lucena JL, de la Fuente S, et al. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. World J Hepatol, 2019, 11(1): 50-64. DOI: 10.4254/wjh.v11.i1.50.
|
| [19] |
Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4): 320-329. DOI: 10.1159/000514313.
|
| [20] |
He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
|
| [21] |
中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组, 中国医师协会肝癌专业委员会. 肝癌转化治疗中肝功能全程管理中国专家共识(2022版)[J/CD]. 肝癌电子杂志, 2023, 10(1): 1-9.
|
| [22] |
Wu J, Liu A, Cui J, et al. Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images[J]. BMC Med Imaging, 2019, 19(1): 23. DOI: 10.1186/s12880-019-0321-9.
|
| [23] |
Xia TY, Zhou ZH, Meng XP, et al. Predicting microvascular invasion in hepatocellular carcinoma using CT-based radiomics model[J]. Radiology, 2023, 307(4): e222729. DOI: 10.1148/radiol.222729.
|
| [24] |
Guo Z, Zhong N, Xu X, et al. Prediction of hepatocellular carcinoma response to transcatheter arterial chemoembolization: a real-world study based on non-contrast computed tomography radiomics and general image features[J]. J Hepatocell Carcinoma, 2021, 8: 773-782. DOI: 10.2147/JHC.S316117.
|
| [25] |
Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics[J]. AJR Am J Roentgenol, 2018, 211(5): 1026-1034. DOI: 10.2214/AJR.18.19507.
|
| [26] |
Hu Y, Xie C, Yang H, et al. Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma[J]. Radiother Oncol, 2021, 154: 6-13. DOI: 10.1016/j.radonc.2020.09.014.
|
| [27] |
Feng L, Liu Z, Li C, et al. Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study[J]. Lancet Digit Health, 2022, 4(1): e8-e17. DOI: 10.1016/S2589-7500(21)00215-6.
|